Uutiset

Uutiset / Ajankohtaista

Linkkien avaamiseen ja lukemiseen tarvitset ilmaisen Acrobat Reader -ohjelman.

Otsikko Lataa koko teksti

16.10.2018

2018 Pasteur-Weizmann/Servier-Price awarded to Professor Michel Sadelain

19.9.2018

September is Blood Cancer & Childhood Cancer Awareness Month

31.8.2018

Servier finalizes acquisition of Shire's oncology branch

26.6.2018

Servier and Galapagos announce start of global ROCCELLA Phase 2 clinical trial with S201086/GLPG1972 in osteoarthritis patients

23.6.2018

New data for trifluridine/tipiracil(LONSURF) in metastatic colorectal cancer presented at ESMO's World Congress on Gastrointestinal Cancer

3.4.2018

Servier and Scandicure enter into agreement to conduct research in the field of metabolic diseases

13.3.2018

WeHealth by Servier and DEEPLINK MEDICAL sign a partnership to develop a new e-health solution in the field of oncology

4.1.2018

Servier and Treventis begins strategic research partnership in degenerative diseases

13.12.2017

Preliminary data from Servier and Pfizer's UCART 19 product candidate shows high complete remission rate across two Phase I adult and periatric acute lymphoblastic leukemia trials

02.11.2017

Servier and Pfizer announce preliminary results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th ASH Annual Meeting

19.10.2017

Servier establishes strategic research alliance with Harvard University

29.6.2017

Servier  and Transgene have become partners to apply viral vectorization technology to the engineering of allogenic CAR-T

3.5..2017

Servier and miRagen extend collaboration for the research, developmant and commercialization of microRNA-targeting therapeutics

26.4.2017

Servier and Vernalis plc announce achievement of 3 milestones in their oncology drug discovery collaboration

25.4.2017

Servier and CTI BioPharma expand licence and collaboration agreemant to develop and commercialize Pixuvri

14.3.2017

Servier and Neurochlore join forces to treat autism in children

28.12.2017

OSE immunotherapeutics and Servier, partnership agreement to develop and commercialise OSE immunotherapeutics' Effi-7, an antagonist of the interleukin-7 receptor.

20.10.2016

New compound shows promise in treating multiple human cancers

23.6.2015

Ivabradiini (Procoralan) rajoitetusti erityiskorvattavaksi 1.7.2015 lähtien

16.6.2015

Taiho Pharmaceutical Co., Ltd. and Servier Enter into a Licence Agreement for Development and Commercialization of an oral Anticancer Drug in Europe

17.4.2015

FDA approves ivabradine for patients with chronic heart failure

12.11.2014

Intarcia and Servier sign ex-U.S. partnership for ITCA 650 in diabetes;Intarcia retains independence & full control in the U.S. & Japan

2.10.2014

Servier new reasearch partnership with the Walter and Eliza Hall Institute to target Achilles' heel of many cancers

26.9.2014

EMA Confirms positive benefit-risk for antidepressant Valdoxan/Thymanax (agomelatine)